Welcome to our dedicated page for NEWCELX SEC filings (Ticker: NLSPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NewcelX Ltd. filings associated with NLSPW document foreign-issuer current reports, registration-statement references, material-event disclosures, shareholder voting matters, capital-structure items, governance matters, and clinical or regulatory updates. The records reflect the company’s public reporting transition from NLS Pharmaceutics-related securities to NewcelX as a Swiss clinical-stage regenerative medicine issuer.
Recent Form 6-K reports furnish press releases and investor presentations covering stem-cell-derived therapies, the NCEL-101 Type 1 Diabetes program, a stem-cell-derived islet replacement platform, and a strategic collaboration involving targeted immune modulation. The filing record also includes security-structure and registration disclosures, including references to Form F-3 registration statements and Form 20-F foreign private issuer reporting status.
NLS Pharmaceutics Ltd. furnished a report stating that on September 10, 2025 it issued a press release titled “Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger.” The report indicates that a related SEC registration statement for the proposed merger between NLS Pharmaceutics and Kadimastem has become effective, and the press release describing this development is attached as Exhibit 99.1.
NLS Pharmaceutics Ltd. furnished a report describing a new press release issued on September 4, 2025. The press release announces that NLS Pharmaceutics and Kadimastem have a Hong Kong patent covering a cell-selection and enrichment technology for IsletRx, a treatment approach aimed at diabetes patients. The 6-K mainly serves to provide this press release to investors as Exhibit 99.1.
NLS Pharmaceutics Ltd. filed a Form 6-K to report that it entered into a seventh amendment to its Agreement and Plan of Merger with Kadimastem Ltd. and NLS Pharmaceutics (Israel) Ltd. The amendment extends the merger agreement’s termination date from August 31, 2025 to October 31, 2025 to allow more time to complete the merger.
The extension is intended to provide additional time for NLS Pharmaceutics to receive and evaluate further comments from the U.S. Securities and Exchange Commission on its pending Form F-4 registration statement for the proposed merger transaction with Kadimastem. The parties state that they remain focused on and committed to completing the merger and are working to satisfy all regulatory and closing requirements.
NLS Pharmaceutics Ltd. has postponed its Extraordinary Shareholders’ Meeting, originally planned for August 25, 2025, to September 16, 2025. The meeting is intended to approve transactions related to the company’s contemplated merger with Kadimastem Ltd.
The delay is meant to give NLS Pharmaceutics more time to receive and review additional comments from the U.S. Securities and Exchange Commission on its pending Form F-4 registration statement and to ensure shareholders receive the most current and complete information before voting. The meeting may be postponed again, and any further changes will be announced via another Form 6-K and a notice to shareholders. No action is required from shareholders at this time.